Table 2 Significantly up- and down-regulated genes that discriminate resistant (R) from sensitive (S) CLL patients and that are common to males (M) and females (F)

trafficking protein, kinesin binding 2

TRAK2

2q33

0.054

0.379

calcium channel, voltage-dependent, P/Q type, alpha 1A subunit

CACNA1A

19p13.2-p13.1

0.116

0.135

contactin associated protein-like 2

CNTNAP2

7q35-q36

0.003

0.060

C-terminal binding protein 1

CTBP1

4p16

0.290

2.344

discs, large (Drosophila) homolog-associated protein 4

DLGAP4

20q11.23

0.164

0.389

DNA polymerase-transactivated protein 6

DNAPTP6

2q33.1

0.199

0.177

developmentally regulated GTP binding protein 2

DRG2

17p11.2

0.320

0.442

G protein pathway suppressor 2

GPS2

17p13

0.430

0.425

HOM-TES-103 tumor antigen-like

HOM-TES-103

12p13.3

0.303

0.446

integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide)

ITGAE

17p13

0.450

0.434

phosphoribosylformylglycinamidine synthase (FGAR amidotransferase)

PFAS

17p13.1

0.320

0.457

pleckstrin homology domain containing, family B (evectins) member 1

PLEKHB1

11q13.5-q14.1

0.203

0.484

RNA binding motif, single stranded interacting protein 1

RBMS1

2q24.2

0.036

0.352

v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3

RELB

19q13.31-q13.32

0.245

3.033

transmembrane protein 33

TMEM33

4p13

0.203

2.013

vesicle-associated membrane protein1, synaptobrevin1

VAMP1

12p

0.287

0.395

vanin 2

VNN2

6q23-q24

0.434

0.424